HKEX: 2186
Interim Report 2026
Earlier from Luye Pharma
- Luye Pharma: Announces 2026 Interim Results
- Luye Pharma: Announces Successful Completion of a U.S. Bridging Clinical Trial of Its Innovative Drug LY03015 (VMAT2 Inhibitor/Sigma-1R...
- Luye Pharma: Announces Positive Phase 2 Results of LY03015, a VMAT2 Inhibitor and Sigma-1R Agonist, for Tardive Dyskinesia in China
- Luye Pharma: Announces First Subject Enrolled in U.S. PK Bridging Clinical Trial of Its VMAT2 Inhibitor/Sigma-1R Agonist LY03015